Ceenu (Oral)
Generic name:lomustine (oral route) [ loe-MUS-teen ]
Drug class:Alkylating agents
Medically reviewed by Drugs.com. Last updated on Apr 23, 2022.
Lomustine causes delayed, dose-related, cumulative, fatal myelosuppression. Monitor blood counts for at least 6 weeks after each dose. Do not administer more than one dose every 6 weeks. Physician and pharmacist should emphasize to patient that overdosage can cause fatal toxicity .
Commonly used brand name(s)
In the U.S.
- Ceenu
- Gleostine
Available Dosage Forms:
- Capsule
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Alkylating Agent
Chemical Class: Nitrosourea
Uses for Ceenu
Lomustine is used alone or in combination with other medicines to treat brain tumors, Hodgkin's disease, and other kinds of cancer. This medicine belongs to the group of medicines known as alkylating agents.
Lomustine interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by lomustine, other effects may occur. Some of these may be serious and must be reported to your doctor. Other effects (e.g., hair loss) may not be serious, but may cause concern. Some effects may not occur for months or years after the medicine is used.
Before you begin treatment with lomustine, you and your doctor should talk about the good this medicine will do as well as the risks of using it.
This medicine is available only with your doctor's prescription.
Before using Ceenu
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies on the relationship of age to the effects of lomustine have not been performed in the pediatric population. However, pediatric-specific problems that would limit the usefulness of this medicine in children are not expected.
Geriatric
No information is available on the relationship of age to the effects of lomustine in geriatric patients. However, elderly patients are more likely to have age-related kidney problems, which may require an adjustment in the dose for patients receiving lomustine.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be ne..